| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/28/2007 | EP1756112A1 Pyrrolobenzimidazolones and their use as antiproliferative agents |
| 02/28/2007 | EP1756111A1 Alkyl substituted indoloquinoxalines |
| 02/28/2007 | EP1756110A1 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR PRODUCTION THE ACTIVE AGENT |
| 02/28/2007 | EP1756109A1 Novel indole derivatives as selective androgen receptor modulators (sarms) |
| 02/28/2007 | EP1756108A2 Azaindoles useful as inhibitors of rock and other protein kinases |
| 02/28/2007 | EP1756106A1 Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 02/28/2007 | EP1756105A1 Substituted imidazo[1,2-a]pyridine compounds and drugs containing substituted imidazo[1,2-a]pyridine compounds |
| 02/28/2007 | EP1756104A1 Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands |
| 02/28/2007 | EP1756103A2 Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors |
| 02/28/2007 | EP1756102A1 8-PHENOXY-GammaCARBOLINE DERIVATIVES |
| 02/28/2007 | EP1756101A2 Androgen receptor modulators and method of treating disease using the same |
| 02/28/2007 | EP1756100A1 Salt of phosphoric acid with 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)-ethoxy] benzy] thiazolidin-2,4-dione and a method of its preparation |
| 02/28/2007 | EP1756097A1 2-styryl-4-oxazole-methanol-ethers and their use as tyrosine kinase inhibitors |
| 02/28/2007 | EP1756096A1 Indolyl derivatives as liver-x-receptor modulators |
| 02/28/2007 | EP1756095A2 Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same |
| 02/28/2007 | EP1756094A1 3-cycloalkylbenzazepines as histamine h3 antagonists |
| 02/28/2007 | EP1756093A1 Processes for preparing gonadotropin releasing hormone receptor antagonists |
| 02/28/2007 | EP1756092A1 Novel inhibitors of rho-kinases |
| 02/28/2007 | EP1756091A1 Non nucleoside reverse transcriptase inhibitors |
| 02/28/2007 | EP1756090A1 Pyrimidine derivatives for the treatment of abnormal cell growth |
| 02/28/2007 | EP1756089A1 Mercaptoimidazoles as ccr2 receptor antagonists |
| 02/28/2007 | EP1756088A1 Quinazoline derivatives as erbb receptor tyrosine kinases |
| 02/28/2007 | EP1756087A1 Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
| 02/28/2007 | EP1756086A1 Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists |
| 02/28/2007 | EP1756085A1 Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline |
| 02/28/2007 | EP1756084A2 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 02/28/2007 | EP1756083A1 3-arylsulfonyl-quinolines as 5-ht6 receptor antagonists for the treatment of cns disorders |
| 02/28/2007 | EP1756082A1 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators |
| 02/28/2007 | EP1756081A1 1,1'-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors |
| 02/28/2007 | EP1756080A1 Chromone derivatives useful as vanilloid antagonists |
| 02/28/2007 | EP1756078A1 Phenylsulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase inhibitors |
| 02/28/2007 | EP1756076A1 Hetroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| 02/28/2007 | EP1756074A1 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 02/28/2007 | EP1756072A2 Purification of progesterone receptor modulators |
| 02/28/2007 | EP1756071A1 Benzoxazolone derivatives, processes for preparing them and their uses |
| 02/28/2007 | EP1756070A2 Crystalline forms of n-desmethylclozapine |
| 02/28/2007 | EP1756069A2 Hiv integrase inhibitors |
| 02/28/2007 | EP1756068A1 Benzimidazoles, method for producing them and the use thereof as drugs |
| 02/28/2007 | EP1756067A1 7-substituted benzimidazoles and their use as inhibitors of gastric acid secretion |
| 02/28/2007 | EP1756066A1 Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity |
| 02/28/2007 | EP1756065A1 Anti-cytokine heterocyclic compounds |
| 02/28/2007 | EP1756064A2 Pyrazole derivatives, compositions containing such compounds and methods of use |
| 02/28/2007 | EP1756063A1 Amido compounds and their use as pharmaceuticals |
| 02/28/2007 | EP1756062A1 Compounds and compositions as ppar modulators |
| 02/28/2007 | EP1756061A1 Therapeutic compounds: pyridine n oxide scaffold |
| 02/28/2007 | EP1756060A1 Therapeutic compounds: pyridine as scaffold |
| 02/28/2007 | EP1756058A1 Histamine-3 receptor antagonists |
| 02/28/2007 | EP1756056A1 Aza-bicyclo[3.1.0]hex-1-yl derivatives active as nk1 antagonists |
| 02/28/2007 | EP1756054A1 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
| 02/28/2007 | EP1756053A1 Process for the preparation of atorvastatin |
| 02/28/2007 | EP1756051A1 Histamine h3 receptor agents, preparation and therapeutic uses |
| 02/28/2007 | EP1756050A1 Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake |
| 02/28/2007 | EP1756044A1 Therapeutic compounds |
| 02/28/2007 | EP1756043A1 Ortho substituted aryl or heteroaryl amide compounds |
| 02/28/2007 | EP1756042A1 Substituted methyl aryl or heteroaryl amide compounds |
| 02/28/2007 | EP1756041A2 Polycationic compounds and uses thereof |
| 02/28/2007 | EP1756040A1 Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| 02/28/2007 | EP1756039A2 Compounds and compositions for delivering active agents |
| 02/28/2007 | EP1756034A2 Antibiotic compound |
| 02/28/2007 | EP1756032A1 Crth2 receptor antagonists |
| 02/28/2007 | EP1756025A1 Sulfonamide derivatives |
| 02/28/2007 | EP1755743A2 Triglycerides, fatty acids, alcohols as cns modulators |
| 02/28/2007 | EP1755683A2 Water-soluble coenzyme q10 inclusion complex with beta-cyclodextrin, process of preparing, and use thereof |
| 02/28/2007 | EP1755682A1 Solid pharmaceutical formulation |
| 02/28/2007 | EP1755681A2 Combination of organic compounds |
| 02/28/2007 | EP1755679A2 Kit for treatment of cancer |
| 02/28/2007 | EP1755678A2 Active substance combination of a carbinol compound and an opioid |
| 02/28/2007 | EP1755677A2 High pressure spray-dry of bioactive materials |
| 02/28/2007 | EP1755676A1 Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins |
| 02/28/2007 | EP1755672A2 Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| 02/28/2007 | EP1755671A1 Therapy of platinum-resistant cancer |
| 02/28/2007 | EP1755669A2 Methods and compositions for specifically targeting human hepatocellular carcinoma cells |
| 02/28/2007 | EP1755665A2 Compositions and methods for mucosal vaccination |
| 02/28/2007 | EP1755650A2 A biomolecule-containing formulation of increased stability |
| 02/28/2007 | EP1755649A1 Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6 |
| 02/28/2007 | EP1755646A2 Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| 02/28/2007 | EP1755638A1 Multiple agent therapy for sexual dysfunction |
| 02/28/2007 | EP1755632A1 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound |
| 02/28/2007 | EP1755625A1 Compositions and methods using same for treating neurodegenerative disorders |
| 02/28/2007 | EP1755624A2 Polycationic antimicrobial therapeutic |
| 02/28/2007 | EP1755623A1 Treatment of lung diseases and pre-lung disease conditions |
| 02/28/2007 | EP1755622A1 Treatment with oxaliplatin and an egfr-inhibitor |
| 02/28/2007 | EP1755621A1 Methods of treating hepatocellular carcinoma with denspm |
| 02/28/2007 | EP1755620A2 Sulphated depolymerised exopolysaccharide derivatives, their preparation and uses |
| 02/28/2007 | EP1755619A2 Anti-adhesive compounds to prevent and treat bacterial infections |
| 02/28/2007 | EP1755618A1 Compositions and methods for treatment of premenstrual dysphoric disorder |
| 02/28/2007 | EP1755617A1 Perfluorocarbon-soluble compounds |
| 02/28/2007 | EP1755616A2 Treatment of ophthalmic conditions with mineralcorticoids |
| 02/28/2007 | EP1755615A1 Supportive treatment of liver disease |
| 02/28/2007 | EP1755614A1 Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome |
| 02/28/2007 | EP1755613A2 Substituted cyclic urea derivatives |
| 02/28/2007 | EP1755612A2 Pyrrolobenzodiazepine therapeutic agents useful in the treatment of leukaemias |
| 02/28/2007 | EP1755611A1 Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| 02/28/2007 | EP1755610A2 Thienopyrimidines and thiazolopyrimidines for use in medicine |
| 02/28/2007 | EP1755609A1 Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| 02/28/2007 | EP1755608A1 Treatment with gemcitabine and an egfr-inhibitor |
| 02/28/2007 | EP1755607A2 Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| 02/28/2007 | EP1755606A1 Quinazolinone derivatives useful as vanilloid antagonists |
| 02/28/2007 | EP1755605A2 Use of (4-alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease |
| 02/28/2007 | EP1755604A2 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |